Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer

被引：0
|
作者：
Chai, Yue
Liu, Jiaxuan
Jiang, Mingxia
He, Maiyue
Wang, Xin
Wang, Yipeng
Yang, Xue
Wang, Jing
Xu, Binghe
Li, Qiao
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-18-12
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II study of eribulin with trasutuzumab for pretreated locally advanced or metastatic HER2-positive breast cancer
    Tsunoda, Nobuyuki
    Hattori, Masaya
    Murata, Toru
    Akahane, Kazuhisa
    Kamei, Keitaro
    Goto, Yasutomo
    Amemiya, Takeshi
    Nishimae, Kazumi
    Kubota, Tomoyuki
    Ito, Yuko
    Kurumiya, Yasuhiro
    Yoshihara, Motoi
    Nakanishi, Kenichi
    Kikumori, Toyone
    Ando, Masahiko
    Nagino, Masato
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [23] Combined lapatinib and paclitaxel in HER2-positive breast cancer
    Castaneda, Carlos A.
    Gomez, Henry L.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 308 - 309
  • [24] Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA)
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sally
    Button, Peter
    Devitt, Bianca
    Forster, Benjamin C.
    Fox, Peter
    Harold, Michael
    Ketheeswaran, Sahisha
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (02) : 267 - 275
  • [25] Combined lapatinib and paclitaxel in HER2-positive breast cancer
    Carlos A. Castañeda
    Henry L. Gomez
    Nature Reviews Clinical Oncology, 2009, 6 : 308 - 309
  • [26] ECONOMIC EVALUATION OF PERTUZUMAB NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY STAGE HER2-POSITIVE BREAST CANCER IN GREECE
    Mylonas, C.
    Kourlaba, G.
    Skroumpelos, A.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A735 - A735
  • [27] Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
    Yardley, Denise A.
    Raefsky, Eric
    Castillo, Raul
    Lahiry, Anup
    LoCicero, Richard
    Thompson, Dana
    Shastry, Mythili
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 297 - 305
  • [28] A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
    Tae-Yong Kim
    Hye Sook Han
    Keun-Wook Lee
    Dae Young Zang
    Sun Young Rha
    Young Iee Park
    Jin-Soo Kim
    Kyung-Hun Lee
    Se Hoon Park
    Eun-Kee Song
    Soo-A Jung
    NaMi Lee
    Yeul Hong Kim
    Jae Yong Cho
    Yung-Jue Bang
    Gastric Cancer, 2019, 22 : 1206 - 1214
  • [29] A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
    Kim, Tae-Yong
    Han, Hye Sook
    Lee, Keun-Wook
    Zang, Dae Young
    Rha, Sun Young
    Park, Young Lee
    Kim, Jin-Soo
    Lee, Kyung-Hun
    Park, Se Hoon
    Song, Eun-Kee
    Jung, Soo-A
    Lee, NaMi
    Kim, Yeul Hong
    Cho, Jae Yong
    Bang, Yung-Jue
    GASTRIC CANCER, 2019, 22 (06) : 1206 - 1214
  • [30] Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study
    van Ramshorst, M. S.
    van Werkhoven, E.
    Mandjes, I. A. M.
    Schot, M.
    Wesseling, J.
    Peeters, M-JTFD Vrancken
    Rodenhuis, S.
    Oosterkamp, H. M.
    Bos, M. E. M.
    Terwogt, J. M. Meerum
    Linn, S. C.
    Sonke, G. S.
    CANCER RESEARCH, 2016, 76
12345